Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)
NCT05280275 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- April 13, 2022
- Completion date
- March 15, 2026
- Enrollment
- 36 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
blood protein disorders, corneal disease, gammopathy, monoclonal, haematologic disease, multiple myeloma, neoplasms, neoplasms, plasma cell, paraproteinemias